Skip to main content

01.12.2017 | Research article | Ausgabe 1/2017 Open Access

BMC Complementary and Alternative Medicine 1/2017

The Chinese medicine JC-001 enhances the chemosensitivity of Lewis lung tumors to cisplatin by modulating the immune response

BMC Complementary and Alternative Medicine > Ausgabe 1/2017
Meng-Hsien Chuang, Ming-Shiou Jan, Jinghua Tsai Chang, Fung-Jou Lu
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​s12906-017-1728-x) contains supplementary material, which is available to authorized users.
Jinghua Tsai Chang and Fung-Jou Lu contributed equally to this work.



JC-001 is a Chinese medicine that can modulate the immunity in Hepa 1-6 tumor-bearing mice, and we questioned whether JC-001 can serve as efficient adjuvant chemotherapy. We aimed to identify a novel approach for enhancing cis-diamminedichloroplatinum (II) (CDDP)-based chemotherapy by immunomodulation.


The anti-tumor activity in vitro was determined based on foci formation and a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. A LLC1 tumor xenograft model was used to analyze the activity of tumor rejection in vivo. The tumors were analyzed through hematoxylin and eosin (H&E) staining, immunohistochemistry (IHC) staining and cytokine arrays.


JC-001 suppressed foci formation and reduced the viability of Lewis lung carcinoma (LLC1) cells in vitro. JC-001 suppressed LLC1 tumor growth in immunodeficient BALB/c nude mice and in immunocompetent C57BL/6 mice to an even greater extent. Furthermore, JC-001 up-regulated interferon-γ expression in the tumor microenvironment, enhanced the Th1 response in tumor-bearing mice, and increased the chemosensitivity of LLC1 tumors to CDDP chemotherapy. The results of our study suggest that JC-001 is associated with low cytotoxicity and can significantly suppress tumor growth by enhancing the Th1 response.


JC-001 is a Chinese medicine with potential clinical applications in CDDP-based chemotherapeutic regimens.
Additional file 1: JC-001 reduced the tumor mass in BALB/c nude immunodeficient mice inoculated with LLC1 subcutaneously. The average tumor weight in the 3X JC-001-treated group (n = 8) was significantly reduced to 39% of that in the control group (n = 8). **p < 0.01 compared with the control group. (DOCX 67kb)
Additional file 2: Relative cytokine levels in the tumor microenvironment (A) and serum (B) in the JC-001-treated group compared with the control group. LLC1 tumor-bearing mice were treated with 3X JC-001 in H2O for 23 days, and cytokine levels in tumor tissues were analyzed by RayBio®mouse cytokine antibody array 3.1. (DOCX 260 kb)
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2017

BMC Complementary and Alternative Medicine 1/2017 Zur Ausgabe